AAAAAA
Results:
1-13
|
Results: 13
Authors:
Rojo, A
Fontan, A
Mena, MA
Herranz, A
Casado, S
de Yebenes, JG
Citation: A. Rojo et al., Tolcapone increases plasma catecholamine levels in patients with Parkinson's disease, PARKINS R D, 7(2), 2001, pp. 93-96
Authors:
Hoenicka, J
Vidal, L
Godoy, M
Ochoa, JJ
de Yebenes, JG
Citation: J. Hoenicka et al., New nonsense mutation in the GTP-cyclohydrolase I gene in L-DOPA responsive dystonia-parkinsonism, MOVEMENT D, 16(2), 2001, pp. 364-366
Authors:
Ruiz, PG
Fontan, A
Cenjor, C
Ulmer, E
Tortosa, EG
Pernaute, RS
Rojo, A
de Yebenes, JG
Citation: Pg. Ruiz et al., Saccade disturbances in Huntington's disease: clinical correlations, NERVENARZT, 72(6), 2001, pp. 437-440
Authors:
de Yebenes, JG
Citation: Jg. De Yebenes, Introduction: pramipexole: a novel dopamine agonist for the treatment of Parkinson's disease, EUR J NEUR, 7, 2000, pp. 1-2
Authors:
Ruiz, PJG
Tortosa, EG
Bernados, VS
Rojo, A
Fontan, A
de Yebenes, JG
Citation: Pjg. Ruiz et al., Bradykinesia in Huntington's disease, CLIN NEUROP, 23(1), 2000, pp. 50-52
Authors:
Sanchez-Pernaute, R
Kunig, G
Alba, AD
de Yebenes, JG
Vontobel, P
Leenders, KL
Citation: R. Sanchez-pernaute et al., Bradykinesia in early Huntington's disease, NEUROLOGY, 54(1), 2000, pp. 119-125
Authors:
Romero, J
Berrendero, F
Perez-Rosado, A
Manzanares, J
Rojo, A
Fernandez-Ruiz, JJ
de Yebenes, JG
Ramos, JA
Citation: J. Romero et al., Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neuronsincreased CB1 receptor mRNA levels in the caudate-putamen, LIFE SCI, 66(6), 2000, pp. 485-494
Authors:
Rojo, A
Pernaute, RS
Fontan, A
Ruiz, PG
Honnorat, J
Lynch, T
Chin, S
Gonzalo, I
Rabano, A
Martinez, A
Daniel, S
Pramstaller, P
Morris, H
Wood, N
Lees, A
Tabernero, C
Nyggard, T
Jackson, AC
Hanson, A
de Yebenes, JG
Citation: A. Rojo et al., Clinical genetics of familial progressive supranuclear palsy, BRAIN, 123, 2000, pp. 419-419
Authors:
Lastres-Becker, I
Romero, J
Berrendero, F
Perez-Rosado, A
Manzanares, J
Rojo, A
Fernandez-Ruiz, J
de Yebenes, JG
Ramos, JA
Citation: I. Lastres-becker et al., Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neuronsincreased cannabinoid CB1 receptor mRNA levels in the rat striatum: Possible therapeutic implications, NEUROTOXIC FACTORS IN PARKINSON'S DISEASE AND RELATED DISORDERS, 2000, pp. 301-305
Authors:
Mena, MA
Casarejos, MJ
de Yebenes, JG
Citation: Ma. Mena et al., The effect of glia-conditioned medium on dopamine neurons in culture. Modulation of apoptosis, tyrosine hydroxylase expression and 1-methyl-4-phenylpyridinium toxicity, J NEURAL TR, 106(11-12), 1999, pp. 1105-1123
Authors:
Hoenicka, J
Perez, M
Perez-Tur, J
Barabash, A
Godoy, M
Vidal, L
Astarloa, R
Avila, J
Nygaard, T
de Yebenes, JG
Citation: J. Hoenicka et al., The tau gene A0 allele and progressive supranuclear palsy, NEUROLOGY, 53(6), 1999, pp. 1219-1225
Authors:
Sanchez-Pernaute, R
Garcia-Segura, JM
Alba, AD
Viano, J
de Yebenes, JG
Citation: R. Sanchez-pernaute et al., Clinical correlation of striatal H-1 MRS changes in Huntington's disease, NEUROLOGY, 53(4), 1999, pp. 806-812
Authors:
Rojo, A
Pernaute, RS
Fontan, A
Ruiz, PG
Honnorat, J
Lynch, T
Chin, S
Gonzalo, I
Rabano, A
Martinez, A
Daniel, S
Pramsteller, P
Morris, H
Wood, N
Lees, A
Tabernero, C
Nyggard, T
Jackson, AC
Hanson, A
de Yebenes, JG
Citation: A. Rojo et al., Clinical genetics of familial progressive supranuclear palsy, BRAIN, 122, 1999, pp. 1233-1245
Risultati:
1-13
|